Dow Up1.31% Nasdaq Up2.40%

Poniard Pharmaceuticals, Inc. (PARD)

-Other OTC
ProfileGet Profile for:
Poniard Pharmaceuticals, Inc.
300 Elliott Avenue West
Suite 530
Seattle, WA 98119
United States - Map
Phone: 206-281-7001
Fax: 206-284-3181

Index Membership:N/A
Full Time Employees:7

Business Summary 

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Poniard Pharmaceuticals, Inc.

Key Executives 
Mr. Michael K. Jackson CPA, 65
Dr. Michael S. Perry DVM, Ph.D., FACVPT, 55
Amounts are as of Dec 31, 2010 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders